
Madeline G AdeeUniversity of California, Berkeley | UCB · School of Public Health
Madeline G Adee
Master of Public Health
About
9
Publications
742
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
82
Citations
Publications
Publications (9)
Introduction
This study aims to assess the public health impact of eliminating a longstanding routine HIV screening program and replacing it with targeted testing. In addition, costs, outcomes, and cost effectiveness of routine screening are compared with those of targeted testing in the Fulton County Jail, Atlanta, Georgia.
Methods
A published ma...
Hepatitis C virus (HCV) affects 58 million worldwide and more than 79% people remain undiagnosed. 1 • Rapid diagnostic tests (RDTs) for HCV can help improve diagnosis and treatment rates. • The high price and infrastructure needed to use current molecular HCV RDT options present a barrier to widespread use-particularly in low-and middle-income coun...
In order to meet the World Health Organization goal of eliminating hepatitis C virus (HCV) as a public health threat by 2030, HCV testing must be scaled up.
Most countries do not have widespread testing programs in place, and cost is a burden to implementation.
We created an interactive online tool to allow countries to assess the cost-effectivene...
Watch a video presentation of this article
Importance
In the US, hepatocellular carcinoma (HCC), primarily associated with hepatitis C virus (HCV) infection, is the fastest rising cause of cancer-related death. Wider use of highly effective direct-acting antiviral agents (DAAs) substantially reduces the burden of chronic HCV infection, but the subsequent impacts with HCV-associated HCC rema...
This cross-sectional study assesses and compares the prevalence of hepatitis C virus among criminal justice populations in New Mexico, a state with high hepatitis C virus prevalence, and Georgia, a state with low hepatitis C virus prevalence.
The cost of treating all incarcerated people who have hepatitis C with direct-acting antiviral agents (DAAs) greatly stresses correctional facility budgets. Complex federal laws bar pharmaceutical companies from simply discounting expensive medications to prices that facilities can afford. This article discusses means by which correctional faciliti...
The justice system provides a strategic setting for hepatitis C virus elimination efforts, as an estimated 30% of HCV infected Americans pass through a jail or prison annually. At current levels of funding for HCV management, prisons are not aggressively seeking cases, and few incarcerated persons with known HCV receive treatment. Using Georgia and...